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Abstract 
Objective. The effects of smoking on disease manifestations in axial spondyloarthritis (axSpA) are 
inadequately described. Utilising a large and well-characterised cohort, we investigated the 
association between smoking and (i) extra-axial manifestations (EAM) and (ii) disease severity 
measures.  
Methods. Baseline data from the British Society for Rheumatology Biologics Register for Ankylosing 
Spondylitis were explored. Our analyses focused on EAMs and other disease severity measures, 
including scales for fatigue, sleep, anxiety and depression. Logistic and linear models were used to 
quantify associations between disease characteristics according to smoking status 
(current/ex/never) and quantity (heavy/light), adjusting for age, gender, BMI, education, 
deprivation, comorbidities, symptom duration and alcohol status. 
Results. A total of 2031 participants were eligible for the current analysis (68% male, mean age 49 
years). 24% were current and 32% ex-smokers. When compared to non-smokers, current smokers 
had lower odds of uveitis (ORadj 0.7, 95%CI 0.5 to 0.9) and higher odds of psoriasis (ORadj 1.6, 95%CI 
1.1 to 2.3). Ex- and current smokers had incrementally more severe disease than never smokers, 
with higher BASDAI (β=0.3, 95%CI 0.1 to 0.6; β=0.9, 95%CI 0.6 to 1.2) and BASFI (β=0.5, 95%CI 0.2 to 
0.8; β=1.3, 95%CI 1.0 to 1.6); similar associations were observed for fatigue, sleep, anxiety and 
depression. 
Conclusions. In this large cross-sectional study, we observed that smoking is independently 
associated with an adverse disease profile in axSpA, including worse fatigue, sleep, anxiety, 
depression and higher odds of psoriasis. The paradoxical association between current smoking and 
reduced odds of uveitis is interesting and warrants further investigation. 
Keywords. Axial spondyloarthritis, ankylosing spondylitis, smoking, uveitis, extra-axial 
manifestations, registry, fatigue, sleep, psoriasis, depression. 
Key messages: 
 Baseline smoking status was independently associated with worse disease in axial 
spondyloarthritis. 
 Smoking was associated with an adverse disease profile, including worse fatigue, sleep, anxiety 
and depression. 
 Current smoking was associated with higher odds of psoriasis but, paradoxically, lower odds of 
uveitis. 
 
Background 
The prevalence of cigarette smoking in axial spondyloarthritis (axSpA) is high in the UK with nearly 
half of patients reporting either current or prior smoking [1-3]. Smoking is associated with earlier 
symptom onset and worse disease activity, functional impairment and quality of life [4, 5]. Among 
smokers, there is evidence of an exposure-response relationship: less severe disease is observed 
with smoking cessation [1] and with lower cumulative pack-year exposure [3]. In longitudinal 
analyses, smokers were less likely to adhere and respond to TNF inhibition (TNFi) therapy [6]. 
However, the causal relationship between smoking and axSpA severity is complex. Smoking is 
frequently associated with socioeconomic factors, health related behaviours and comorbidity. It is 
essential to adjust for these factors when exploring whether smoking has independent effects on the 
disease and is therefore a potentially modifiable risk factor that could improve outcomes. 
There has been no focused analysis of smoking and extra axial manifestations (EAM). Up to quarter 
of axSpA patients have acute anterior uveitis (AAU) and a similar proportion have peripheral joint 
involvement, whilst 9% and 7% of patients have psoriasis and inflammatory bowel disease (IBD), 
respectively [7, 8]. These EAMs can influence treatment, impact allocation of health resources and 
affect prognosis [7, 9, 10]; exploring their association with smoking is therefore of clinical relevance. 
Although AAU, psoriasis and IBD are each known to be associated with smoking as independent 
disease entities [11-13], these associations have not been examined in the context of axSpA. In 
addition, associations between smoking and several important disease related outcomes have not 
yet been described, such as fatigue, sleep, anxiety and depression that form key components of 
holistic care. 
Our aim was to use a large and well-characterised national axSpA register to provide an improved 
description of the associations between smoking and (i) extra-axial manifestations including AAU, 
psoriasis, IBD, dactylitis, peripheral arthritis and enthesitis, and (ii) other disease severity measures, 
including fatigue, sleep, anxiety and depression. 
Methods 
The British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) is a 
UK-wide prospective cohort study of axSpA patients fulfilling the ASAS criteria for axial SpA. The 
study protocol has been previously published [14]. This analysis focused on baseline cross-sectional 
data before any exposure to biologic therapy, from December 2012 to June 2017. Participants were 
included in this analysis if they completed the smoking status question of the questionnaire. 
Data were obtained from patient completed questionnaires and extracted from medical records by 
participating centres. Clinical data at the time of recruitment included: all components of ASAS and 
modified New York criteria [15, 16], symptom duration and body mass index (BMI). A targeted 
medical history included extra-axial manifestations (EAM) and use of NSAIDs or DMARDs in the past 
six months. Physician-confirmed diagnoses of AAU, psoriasis and IBD were used, whilst peripheral 
arthritis, dactylitis and enthesitis were derived from each participant’s clinical record. A list of 
comorbidities was also obtained from clinical records [14]. The number of comorbidities were added 
and categorised as 0, 1, 2 or ≥3. 
Participant questionnaires captured smoking status as never, ex- or current smokers at baseline. Ex- 
and current smokers were asked their frequency of smoking in the past three months; ex-smokers 
were defined as those who had not smoked in this period. Current smokers reported average 
number of cigarettes smoked per day, and were grouped as light smokers (≤10 cigarettes/day, the 
median quantity) or heavy smokers (>10 cig/day). Alcohol exposure was categorised as current, ex- 
or never drinkers. Socioeconomic status was approximated using post-code derived Index of 
Multiple Deprivation (IMD) for each country of the UK, with quintile 1 representing the top 20% 
most deprived areas and quintile 5 the least deprived [17, 18].  
Disease activity was assessed using the Bath AS Disease Activity Index (BASDAI), AS Disease Activity 
Score (ASDAS), spinal pain visual analogue scale, CRP (mg/dl) and ESR (mm/hr); functional 
impairment using Bath AS Functional (BASFI) and Metrology Indices (BASMI); quality of life using AS 
quality of life questionnaire (ASQoL) and EuroQoL (EQ-5D and EQ-VAS) [19]. Additional measures 
included the Bath AS Global Score (BASG), Chalder Fatigue Scale Likert scale (CFQ) [20], Jenkins Sleep 
Evaluation Questionnaire [21] and the Hospital Anxiety and Depression Scale (HADS) [22]. Properties 
of these measures are described in [23, 24] or their respective references; they are collectively 
referred to as measures of disease severity throughout the text. 
Ethical approval was obtained from the National Research Ethics Service Committee North 
East—County Durham and Tees Valley (reference 11/NE/0374) and informed consent was 
obtained from all participants. 
Analysis 
Descriptive statistics were used to compare participant and disease characteristics (measures of 
disease severity and proportions of EAMs) according to smoking status (current, ex- and never) and 
quantity (heavy vs light among current smokers). 
Logistic and linear models were generated for each EAM and each measure of disease severity, as 
dependent variables, respectively. The independent variables of interest were (i) smoking status and 
(ii) smoking quantity. First, models were adjusted for potential confounders (age, gender, BMI, 
education and IMD). Models were then additionally adjusted for the number of comorbidities, 
symptom duration and alcohol use. These variables were considered separately since their roles as 
confounders are less clear: smoking causes several comorbidities and is associated with earlier 
symptom onset, making these variables potential mediators. Alcohol use is associated with disease 
activity [25] but it is unclear whether as a cause or consequence. 
Interaction terms between smoking and all other covariates were tested. IMD, education, number of 
comorbidities and alcohol status were entered into models as dummy variables. Smoking status was 
entered as a dummy variable, which allowed pairwise comparisons to be derived from a single 
model by changing the reference group: first with never smokers as the reference group (for 
current/never and ex-/never comparisons), then with ex-smokers as reference group (for 
current/ex- comparison; never/ex- comparison was omitted). CRP and ESR were transformed using 
ln(CRP+1) and ln(ESR). No correction was made for multiple comparisons, since many disease 
severity measures are closely related constructs and their analysis do not constitute completely 
independent tests. 
Sensitivity analyses 
Dichotomisation of smoking quantity was arbitrary; therefore we repeated regression models with 
cigarettes per day as a continuous independent variable. Not all participants responded to smoking 
questions. To address potential nonparticipation bias, all models were weighted for the inverse of 
the sampling fraction, where responder and non-responder characteristics were different. This 
allows data from under-represented groups to be weighted more heavily in the models. All analyses 
were performed using Stata version 13. 
Results 
Among a total of 2420 participants with baseline data, 2031 (84%) reported smoking status and 
formed the cohort for analysis. This cohort was mostly male (68%) with mean age of 49.0 years (SD 
14.5). The median symptom duration was 20 years. Criteria for AS was fulfilled by 1431 (70%) and 
ASAS imaging criteria for axSpA by 1824 (90%). HLA-B27 status was available for 74% participants 
and was positive in 79% of these cases. The mean BMI was 27.7kg/m2. 76% reported current alcohol 
use, 17% previous and 7% never. Current smoking was reported by 490 (24%) participants and 
previous smoking by 652 (32%), whilst 889 (44%) had never smoked. Among current smokers, 199 
(55%) were light smokers and 166 (45%) heavy. 
AAU was diagnosed in 483 (24%) participants, psoriasis in 233 (12%) and IBD in 216 (11%). A history 
of peripheral arthritis was recorded for 794 (41%) participants, dactylitis for 169 (9%) and enthesitis 
for 470 (24%). At least one comorbidity was present in 875 (44%) participants: hypertension was 
recorded in 377 (19%) participants, 312 (16%) had depression, 195 (10%) asthma, 94 (4.7%) 
diabetes, 79 (4.2%) cancer, 65 (3.2%) peptic ulcer, 40 (2.0%) myocardial infarction, 35 (1.7%) renal 
disease, 33 (1.6%) chronic bronchitis/emphysema, 28 (1.4%) unstable angina, 27 (1.3%) stroke, 20 
(1.0%) heart failure and 15 (0.8%) liver disease. 
Participant characteristics compared between smoking status/quantity 
Table 1 compares participant characteristics between current, ex- and never smokers, and between 
heavy and light smokers. Never smokers were more likely to be female than current or ex-smokers. 
Never smokers also showed trends for having higher educational attainment, lower deprivation and 
fewer comorbidities. 
Ex-smokers were the oldest group with longest symptom duration. They had higher prevalence of 
radiographic sacroiliitis and, as a result, were more likely to meet criteria for AS. Current smokers 
were less likely to be current alcohol drinkers. They were less likely to meet the ASAS criteria “good 
response to NSAIDs” but were more likely to have “elevated CRP.” Current smokers were less likely 
to be current drinkers than ex- or never smokers. 
Heavy smokers (>10 cigarettes/day) were older and had higher BMI than light smokers (≤10). All 
other characteristics were similar between heavy and light smokers. 
Extra-axial manifestations and smoking status/quantity 
Proportions of each EAM for current, ex- and never smokers are shown in Table 2. Adjusting for 
confounders, current smokers had 32% and 30% lower odds of AAU than either never (ORadj 0.68; 
95%CI 0.49 to 0.94) or ex-smokers (ORadj 0.70; 95%CI 0.50 to 0.99), respectively (Table 3). Current 
smokers had 56% and 66% higher odds of psoriasis than never (ORadj 1.56; 95%CI 1.05 to 2.32) or ex-
smokers (ORadj 1.66; 95%CI 1.09 to 2.54), respectively. Ex-smokers were 40% more likely to have a 
history of IBD, although this was not statistically significant (ORadj 1.40; 95%CI 0.96 to 2.03). There 
were no significant differences in other EAMs. 
Proportions of EAMs were not statistically different between heavy and light smokers in unadjusted 
(Table 2) or adjusted (Supplementary table 1) comparisons. 
Measures of disease severity and smoking status/quantity 
A selection of disease severity measures according to each smoking categorisation are shown in 
Table 2; other disease severity measures are shown in supplementary table 2. All measures were 
significantly different between current, ex- and never smokers, except ESR. Table 3 and 
supplementary table 3 show the differences between categories of smoking status from fully 
adjusted regression models. Results from partially adjusted models are shown in Supplementary 
table 4. Current smokers had more severe disease than never smokers in terms of disease activity 
(0.9 units higher BASDAI, 0.5 units higher ASDAS) and functional impairment (1.3 units higher BASFI, 
0.6 units higher BASMI). Compared to never smokers, current smokers also reported worse quality 
of life (ASQoL higher by 2.6 units), fatigue (higher by 1.3 units), sleep (higher by 0.8 units) and 
anxiety and depression (1.9 units higher for both sub-scores). CRP was higher in current than never 
smokers but ESR was not.  
When current smokers were compared with ex-smokers, effect sizes were smaller than above 
comparisons but nevertheless significant. Current smokers had worse disease activity (0.6 units 
higher BASDAI), functional impairment (0.8 units higher BASFI) and depression (1.3 units higher). 
Current smokers also had higher CRP than those who had quit. 
Differences in measures of disease severity were smaller between ex- and never smokers than the 
above comparisons. Previously observed differences in CRP and EQ5D were no longer significant 
between ex- and never smokers. 
Heavy smokers had worse function (BASFI and BASMI) than light smokers (Table 2 and 
supplementary table 2). However, the differences were not statistically significant in adjusted 
models (Supplementary table 1). 
Sensitivity analyses 
Regression models exploring the association between smoking quantity (in units of 5 cigarettes per 
day) and EAMs and other measures of disease severity remained non-significant (supplementary 
table 1). Smoking data was missing for 16% of the cohort; among these 72% had missing 
questionnaires. Participants with smoking data were older (mean age 49.0 vs 43.6 years, P<0.001) 
with longer symptom duration (median 20.0 vs 14.8 years, P<0.001) than non-responders. There was 
also trend to suggest that responders were less deprived and had more comorbidities. All other 
participant characteristics were statistically similar (supplementary table 5). Applying inverse 
sampling weights derived from these variables did not significantly change effect estimates 
(Supplementary table 6). 
Interactions between gender and smoking status/quantity 
The only significant interaction was between gender and smoking status. Current smokers of both 
genders had worse disease than never smokers. However, the difference between current and ex-
smokers were more consistently observed in males. In females, the effect sizes for AAU (ORadj 0.53; 
05%CI 0.29 to 0.97) and psoriasis (ORadj 2.48; 95%CI 1.28 to 4.81) were larger, although differences 
between the sexes were not statistically significant (supplementary table 6). There were no 
significant interactions between gender and smoking quantity (results not shown). 
 
Discussion 
In this large national cross-sectional study, we found that current smoking was associated with 
higher odds of psoriasis and, intriguingly, around 30% lower odds of AAU than either ex- or never 
smokers. We also observed that previous and current smoking exposures were independently 
associated with incrementally more severe axSpA disease compared to never smoking; this included 
worse fatigue, sleep, anxiety and depression. These associations remained statistically and clinically 
significant despite adjusting for important confounders. 
A major strength of this study was the quality of data available from the largest cross-sectional 
cohort to date. This allowed the potential effects of smoking to be quantified in detail and for 
adjustment for important confounding variables. Participants were recruited from both specialist 
and non-specialist secondary care centres, thus providing a relatively unselected population. 
Furthermore, this biologic naïve cohort allowed disease severity to be assessed independent of TNF 
inhibition therapy. 
This observational study used data from an established cohort. Whilst smoking has been recorded in 
detail, information on pack-years and time since smoking cessation were not recorded. This impacts 
our interpretation of results and may also explain the lack of associations between smoking quantity 
and disease severity seen in previous studies using pack-years [3]. These cross-sectional effect sizes 
were large and should be interpreted with caution; those with more severe disease may also alter 
their smoking behaviour. The effect of smoking on treatment response was more subtle in 
longitudinal studies [26, 27]. However, effect sizes in our study were consistent with existing cross-
sectional studies [1, 3, 5] and may be clinically important given that ≥2-unit improvement in BASDAI 
is considered as response to TNF inhibition therapy. The median BASDAI of this cohort was high, but 
similar to other cross-sectional cohorts [3, 4]. 
The limitation for causation applies particularly to the counterintuitive finding between smoking and 
AAU. This association had been observed previously [1, 3, 28]. A proposed explanation was that 
irritation from cigarette smoke cause patients with AAU to change their behaviour and to stop 
smoking. However, AAU attacks are typically paroxysmal, with long periods of remission in between. 
It is therefore less likely to influence permanent lifestyle change than persistent disease features, 
such as psoriasis. This study is the first to show that never smokers also had higher odds of AAU than 
current smokers, adjusting for symptom duration. It could also be argued that patients with AAU 
would avoid smoking altogether. However, the majority of regular smoking starts before 18 years of 
age in Europe [29]; this is likely to precede the first attack of AAU, the risk of which increases with 
longer symptom duration [7]. Studying the relationship between smoking and AAU within a 
population of axSpA patients effectively conditions on a potential collider (a common effect of 
smoking and unmeasured confounders between axSpA and uveitis). Such selection bias can induce 
paradoxical associations between smoking and AAU; for example smoking increases risk of psoriatic 
arthritis in the general population, but reduces its risk among those with psoriasis [30]. Further 
exploration of smoking and axSpA-associated AAU is warranted to establish whether this is a 
statistical or biological phenomenon: A similar lack of smokers had been observed among patients 
with ulcerative colitis (UC), a condition in which AAU is the most prevalent extra-intestinal feature 
[31]. Increased risk of UC in both ex- and never smokers is now accepted, although the mechanism 
remains unclear [12].  
The associations between smoking and disease severity are likely explained, at least in part, by the 
inflammatory effects of smoke inhalation: current smokers had higher CRP. This systemic 
inflammatory burden may exacerbate the localised disease process in axSpA, as supported by more 
current smokers having active inflammation on MRI. Interestingly, the prevalence of current 
smoking in this axSpA cohort is higher than that previously reported in the equivalent UK register for 
RA (21%) – a disease with greater aetiological links to smoking [32]. Smoking in axSpA may cause 
additional inflammatory burden that contributes to the development of more extensive 
inflammatory lesions that can be detected on MRI. 
Our results also suggest that some covariates may mediate some of smoking’s effect on disease 
severity, indicated by the reduced effect sizes in fully adjusted models. The fact that these 
associations with smoking persist despite adjusting for potential mediators supports the hypothesis 
that smoking has an important direct effect on disease severity. The cross-sectional nature of this 
study precluded formal mediation analysis, which should be a focus of future longitudinal studies. 
The interaction between gender and smoking was interesting. However, these findings should be 
interpreted cautiously, since they were not generated from an a priori hypothesis. 
Summary 
Using a large and well-characterised national cohort of patients with axSpA, we provide clear 
evidence that previous and current smoking are associated with incrementally worse disease across 
a wide range of severity measures. We also found that current smoking was associated with higher 
odds of psoriasis and lower odds of AAU than either ex- or never smokers. The latter novel finding 
warrants longitudinal investigation. 
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Table 1. Differences in patient and disease characteristics according to smoking status and quantity. 
 Smoking status Smoking quantity+ 
Never smoker 
(n=890) 
Ex-smoker (n=652) Current smoker 
(n=489) 
P-
value 
Light smoker 
(n=199) 
Heavy smoker 
(n=166) 
P-
value 
Age, mean (SD) years 47.6 (14.8) 54.2 (13.6) 44.5 (12.9) <0.001 42.7 (13.4) 47.6 (11.6) <0.001 
Male 562 (63%) 459 (70%) 356 (73%) <0.001 139 (70%) 127 (77%) 0.154 
Meets mNY criteria for AS 597 (67%) 499 (77%) 335 (69%) <0.001 139 (70%) 117 (70%) 0.895 
HLA-B27 positive+ 530 (77%) 375 (82%) 283 (79%) 0.179 126 (82%) 89 (79%) 0.533 
Radiographic sacroiliitis* 597 (82%) 499 (88%) 335 (85%) 0.003 139 (85%) 117 (88%) 0.500 
Inflammatory lesion on MRI+ 483 (81%) 299 (75%) 295 (88%) <0.001 109 (84%) 104 (90%) 0.127 
Good response to NSAIDs 614 (71%) 434 (70%) 266 (58%) <0.001 99 (53%) 99 (62%) 0.091 
Elevated CRP** 432 (50%) 324 (52%) 286 (62%) <0.001 119 (64%) 103 (65%) 0.877 
Symptom duration, median (IQR) 
years 
18.5 (7.9 to 32.5) 27.3 (13.0 to 37.1) 15.1 (6.9 to 27.0) <0.001 13.2 (6.2 to 26.3) 18.0 (7.8 to 29.1) 0.096 
BMI, mean (SD) 27.5 (5.6) 28.6 (5.1) 27.1 (5.8) <0.001 26.6 (5.7) 28.2 (6.0) 0.018 
Quintiles of 
Index of 
Multiple 
Deprivation 
1, most deprived 94 (11%) 83 (13%) 132 (27%) <0.001
*** 
57 (29%) 46 (28%) 0.365*
** 2 149 (17%) 98 (15%) 99 (20%) 39 (20%) 38 (23%) 
3 188 (21%) 145 (22%) 102 (21%) 31 (16%) 35 (21%) 
4 220 (25%) 177 (27%) 93 (19%) 41 (21%) 31 (19%) 
5, most affluent 239 (27%) 149 (23%) 63 (13%) 31 (16%) 16 (10%) 
Highest level 
of education 
Secondary school 219 (25%) 231 (36%) 199 (41%) <0.001 82 (42%) 78 (48%) 0.290 
Apprenticeship 66 (7%) 65 (10%) 55 (11%) 23 (12%) 25 (15%) 
Further education 
college 
273 (31%) 211 (33%) 133 (28%) 57 (29%) 42 (26%) 
University degree 232 (26%) 99 (15%) 69 (14%) 26 (13%) 12 (7%) 
Further degree 94 (11%) 41 (6%) 27 (6%) 7 (4%) 7 (4%) 
Alcohol status Current 698 (79%) 494 (76%) 330 (68%) <0.001 17 (9%) 18 (11%) 0.444 
Ex 114 (13%) 122 (19%) 113 (23%) 53 (27%) 36 (22%) 
Never 67 (8%) 33 (5%) 42 (9%) 126 (64%) 112 (67%) 
Number of 
comorbidities 
0 554 (63%) 318 (50%) 264 (54%) <0.001
*** 
111 (56%) 81 (49%) 0.279*
** 1 228 (26%) 186 (29%) 152 (31%) 58 (29%) 60 (36%) 
2 75 (9%) 87 (14%) 50 (10%) 22 (11%) 18 (11%) 
≥3 24 (3%) 50 (8%) 23 (5%) 8 (4%) 7 (4%) 
Medication in 
the past 6 
months 
NSAIDs  667 (76%) 443 (69%) 381 (78%) <0.001 150 (75%) 132 (80%) 0.347 
DMARDs 95 (16%) 57 (13%) 43 (12%) 0.310 12 (9%) 16 (13%) 0.210 
Data presented as mean (standard deviation), median (interquartile range), number (percentage). Comparisons used t-test for continuous variables, Chi-squared 
test for categorical variables. Bold text highlights significant differences. 
+Not all current smokers provided information on smoking quantity. Not all variables have complete data, in particular: HLA-B27 status tested in 1773 and MRI 
results were available for 1606. 
*Radiographic sacroiliitis defined as grade 2 or more bilaterally or grade 3 or greater unilaterally. 
**Above upper normal limit. 
***Non-parametric test for trend across ordered groups. 
SD, standard deviation; IQR, interquartile range; mNY, modified New York criteria; BMI, body mass index. 
 
 Table 2. Differences in extra-axial manifestations and measures of disease severity according to smoking status and quantity. A selection of 
disease severity measures is shown here with other variables shown in supplementary table 2. 
 Smoking status Smoking quantity+ 
Never smoker 
(n=890) 
Ex-smoker 
(n=652) 
Current 
smoker 
(n=489) 
P-
value 
Light smoker 
(n=199) 
Heavy smoker 
(n=166) 
P-
value 
Extra axial 
manifestations, 
n (%) 
Uveitis 241 (27%) 166 (26%) 76 (16%) <0.001 29 (15%) 30 (18%) 0.366 
IBD 87 (10%) 82 (13%) 47 (10%) 0.135 19 (10%) 12 (7%) 0.429 
Psoriasis 87 (10%) 77 (12%) 69 (14%) 0.058 24 (12%) 26 (16%) 0.319 
Peripheral 
arthritis 
358 (41%) 270 (43%) 166 (36%) 0.044 66 (35%) 60 (38%) 0.665 
Dactylitis 75 (9%) 58 (9%) 36 (8%) 0.672 15 (8%) 14 (9%) 0.805 
Enthesitis 211 (24%) 156 (25%) 103 (22%) 0.546 44 (24%) 34 (21%) 0.615 
Disease activity, 
median (IQR) 
BASDAI 4.3 (2.2 to 6.4) 4.9 (2.7 to 6.7) 6.1 (4.1 to 7.5) <0.001 6.1 (4.4 to 7.4) 6.4 (4.7 to 7.6) 0.403 
ASDAS+ 2.1 (1.3 to 2.9) 2.3 (1.5 to 3.0) 2.8 (2.1 to 3.4) <0.001 2.7 (2.1 to 3.4) 2.9 (2.3 to 3.6) 0.114 
BASFI, median (IQR) 3.4 (1.4 to 6.0) 5.0 (2.4 to 7.3) 5.9 (3.5 to 8.1) <0.001 5.8 (3.7 to 7.9) 6.8 (4.9 to 8.3) 0.026 
ASQoL, median (IQR) 6 (2 to 11) 8.5 (3 to 13) 12 (7 to 16) <0.001 12 (8 to 16) 13 (9 to 16) 0.373 
Chalder Fatigue Scale, median 
(IQR) 
14 (11 to 19) 14 (11 to 18) 17 (11 to 21) <0.001 17 (12 to 21) 17 (12 to 20) 0.466 
Sleep, median (IQR) 9 (4 to 15) 10 (5 to 16) 13 (6 to 17) <0.001 12 (6 to 17) 14 (9 to 18) 0.057 
HADS, median 
(IQR) 
Anxiety 6 (3 to 10) 7 (4 to 11) 10 (6 to 13) <0.001 10 (6 to 13) 10 (6 to 13) 0.555 
Depression 4 (2 to 7) 5 (3 to 9) 8 (4 to 11) <0.001 8 (4 to 11) 8 (4 to 11) 0.623 
Bold text highlights significant differences. 
+Not all current smokers provided information on smoking quantity. 1596 patients had ASDAS. 
IQR, interquartile range; BASDAI, Bath AS disease activity index; ASDAS, AS disease activity score; BASFI, Bath AS functional index; ASQoL, AS 
quality of life questionnaire; Sleep, Jenkins Sleep Evaluation Questionnaire; HADS, Hospital Anxiety and Depression Scale; IBD, inflammatory 
bowel disease. 
 
 Table 3. Comparisons between current, ex- and never smokers using fully adjusted regression models. A selection of disease 
severity measures is shown here with other variables shown in supplementary table 3. 
 Never 
smokers 
Ex-smokers Current smokers Ex-
smokers 
Current smokers 
Extra axial 
manifestations 
Uveitis Reference 0.97 (0.74 to 1.27) 0.68 (0.49 to 0.94) Reference 0.70 (0.50 to 0.99) 
IBD Reference 1.40 (0.96 to 2.03) 1.03 (0.66 to 1.61) Reference 0.73 (0.47 to 1.14) 
Psoriasis Reference 0.94 (0.64 to 1.37) 1.56 (1.05 to 2.32) Reference 1.66 (1.09 to 2.54) 
Peripheral 
arthritis 
Reference 0.93 (0.73 to 1.19) 0.82 (0.62 to 1.08) Reference 0.88 (0.65 to 1.17) 
Dactylitis  Reference 1.07 (0.71 to 1.60) 1.08 (0.68 to 1.72) Reference 1.02 (0.62 to 1.65) 
Enthesitis  Reference 1.05 (0.80 to 1.38)  0.89 (0.65 to 1.22)  Reference 0.85 (0.61 to 1.18) 
Disease activity BASDAI Reference 0.35 (0.08 to 0.62) 0.94 (0.64 to 1.24) Reference 0.59 (0.27 to 0.91) 
ASDAS Reference 0.14 (0.01 to 0.28) 0.46 (0.32 to 0.61) Reference 0.32 (0.17 to 0.47) 
BASFI Reference 0.53 (0.24 to 0.82) 1.30 (0.97 to 1.62) Reference 0.77 (0.42 to 1.11) 
ASQoL Reference 0.88 (0.30 to 1.47) 2.64 (1.98 to 3.29) Reference 1.75 (1.06 to 2.44) 
Chalder Fatigue Scale Reference 0.02 (-0.60 to 0.63) 1.34 (0.66 to 2.02) Reference 1.32 (0.60 to 2.05) 
Sleep Reference 0.72 (0.02 to 1.42) 1.89 (1.11 to 2.67) Reference 1.17 (0.35 to 2.00) 
HADS Anxiety Reference 0.75 (0.25 to 1.26) 1.86 (1.30 to 2.42) Reference 1.11 (0.52 to 1.70) 
Depression Reference 0.63 (0.19 to 1.06) 1.9 (1.41 to 2.38) Reference 1.27 (0.75 to 1.79) 
Results shown as regression coefficients β (95%confidence interval) for disease severity markers and odds ratios (95%CI) for extra-
axial manifestations. Bold text highlights significant coefficients and odds ratios. 
BASDAI, Bath AS disease activity index; ASDAS, AS disease activity score; BASFI, Bath AS functional index; ASQoL, AS quality of life 
questionnaire; Sleep, Jenkins Sleep Evaluation Questionnaire; HADS, Hospital Anxiety and Depression Scale; IBD, inflammatory 
bowel disease. 
 
